FOR IMMEDIATE RELEASE March 12, 2018 kim.treanor@keionline.org (202)-332-2670 A coalition of 16 advocacy organizations in the United States and Korea asked trade negotiators in the U.S. and Korea to reject the demands of the pharmaceutical industry, protect human rights, and… Continue Reading
In a resolution dated the 9th of March, 2018, Minister Carmen Castillo Taucher of Chile’s Ministry of Health has announced that there are sufficient public health reasons to support a compulsory license on medicines for the hepatitis C virus (HCV),… Continue Reading
On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading
This is an update to a 2007 report regarding a district court decision in the Innogenetics v. Abbott case here, regarding Abbott’s infringement of Innogenetics’s patents for HCV genotyping. The previous blog discusses the ruling at the district court level… Continue Reading
On Tuesday, 6 March 2018, Cristina Pucarinho, the Deputy Permanent Representative of Portugal to the United Nations made the following intervention at a UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030… Continue Reading
World Health Assembly, May 2001 Statements May 21, 2001. Health GAP Report on the 54th World Health Assembly. May 18, 2001. CPT/Essential Action Comments on the World Health Assembly. May 17, 2001. HealthGAP Coalition Release on the World Health Assembly.… Continue Reading
WHA 71 WHA 70 WHA 69 WHA 69: Colombian Minister of Health Calls on WHO to Support the Regulation of Drug Monopolies, May 25, 2016 WHA 68 WHA 67 WHA 66 WHA 65 … WHA 59 Colombian Submission to the… Continue Reading
KEI page on Research and Development Cost Transparency Legislation EB142: KEI statement on Addressing the global shortage of, and access to, medicines and vaccines, January 24th, 2018 Expert Panel charts a road map for WHO’s engagement on transparency and R&D,… Continue Reading
On Tuesday, 27 February 2018, the representative of the Republic of South Africa delivered the following statement at the World Trade Organization’s TRIPS Council; South Africa delivered this statement under the agenda item on IP and the Public Interest: Regulatory… Continue Reading
KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading